TY - JOUR
T1 - HLA class ii specificity assessed by high-density peptide microarray interactions
AU - Osterbye, Thomas
AU - Nielsen, Morten
AU - Dudek, Nadine L.
AU - Ramarathinam, Sri H.
AU - Purcell, Anthony W.
AU - Schafer-Nielsen, Claus
AU - Buus, Soren
N1 - Funding Information:
This work was supported by The Danish Council for Independent Research (DFF - 6110-00644), Scleroseforeningen (A31444), the European Commission (278832), and the Department of Health, National Health and Medical Research Council (1165490).
Funding Information:
This work was supported by The Danish Council for Independent Research (DFF – 6110-00644), Scleroseforeningen (A31444), the European Commission (278832), and the Department of Health, National Health and Medical Research Council (1165490).
Publisher Copyright:
Copyright © 2020 by The American Association of Immunologists, Inc.
PY - 2020/7/1
Y1 - 2020/7/1
N2 - The ability to predict and/or identify MHC binding peptides is an essential component of T cell epitope discovery, something that ultimately should benefit the development of vaccines and immunotherapies. In particular, MHC class I prediction tools have matured to a point where accurate selection of optimal peptide epitopes is possible for virtually all MHC class I allotypes; in comparison, current MHC class II (MHC-II) predictors are less mature. Because MHC-II restricted CD4+ T cells control and orchestrated most immune responses, this shortcoming severely hampers the development of effective immunotherapies. The ability to generate large panels of peptides and subsequently large bodies of peptide-MHC-II interaction data are key to the solution of this problem, a solution that also will support the improvement of bioinformatics predictors, which critically relies on the availability of large amounts of accurate, diverse, and representative data. In this study, we have used rHLA-DRB1∗01:01 and HLA-DRB1∗03:01 molecules to interrogate high-density peptide arrays, in casu containing 70,000 random peptides in triplicates. We demonstrate that the binding data acquired contains systematic and interpretable information reflecting the specificity of the HLA-DR molecules investigated, suitable of training predictors able to predict T cell epitopes and peptides eluted from human EBV-transformed B cells. Collectively, with a cost per peptide reduced to a few cents, combined with the flexibility of rHLA technology, this poses an attractive strategy to generate vast bodies of MHC-II binding data at an unprecedented speed and for the benefit of generating peptide-MHC-II binding data as well as improving MHC-II prediction tools.
AB - The ability to predict and/or identify MHC binding peptides is an essential component of T cell epitope discovery, something that ultimately should benefit the development of vaccines and immunotherapies. In particular, MHC class I prediction tools have matured to a point where accurate selection of optimal peptide epitopes is possible for virtually all MHC class I allotypes; in comparison, current MHC class II (MHC-II) predictors are less mature. Because MHC-II restricted CD4+ T cells control and orchestrated most immune responses, this shortcoming severely hampers the development of effective immunotherapies. The ability to generate large panels of peptides and subsequently large bodies of peptide-MHC-II interaction data are key to the solution of this problem, a solution that also will support the improvement of bioinformatics predictors, which critically relies on the availability of large amounts of accurate, diverse, and representative data. In this study, we have used rHLA-DRB1∗01:01 and HLA-DRB1∗03:01 molecules to interrogate high-density peptide arrays, in casu containing 70,000 random peptides in triplicates. We demonstrate that the binding data acquired contains systematic and interpretable information reflecting the specificity of the HLA-DR molecules investigated, suitable of training predictors able to predict T cell epitopes and peptides eluted from human EBV-transformed B cells. Collectively, with a cost per peptide reduced to a few cents, combined with the flexibility of rHLA technology, this poses an attractive strategy to generate vast bodies of MHC-II binding data at an unprecedented speed and for the benefit of generating peptide-MHC-II binding data as well as improving MHC-II prediction tools.
UR - http://www.scopus.com/inward/record.url?scp=85088359174&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.2000224
DO - 10.4049/jimmunol.2000224
M3 - Article
C2 - 32482711
AN - SCOPUS:85088359174
SN - 0022-1767
VL - 205
SP - 290
EP - 299
JO - Journal of Immunology
JF - Journal of Immunology
IS - 1
ER -